Structurally Modified Analogues of Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) As Future Antidiabetic Agents

By  

Current Pharmaceutical Design, Vol. 10, Iss. 29, 2004-11 ,pp. : 3651-3662

Bentham Science Publishers

Access to resources Recommend Favorite

Antidiabetic effect of chronic administration of JTT-608, a new hypoglycemic agent, in diabetic Goto-Kakizaki rats

By Ohta T.   Miyajima K.   Komuro G.   Furukawa N.   Yonemori F.  

European Journal of Pharmacology, Vol. 476, Iss. 1, 2003-08 ,pp. : 159-166

Elsevier

Access to resources Recommend Favorite

JTT-608 controls blood glucose by enhancement of glucose-stimulated insulin secretion in normal and diabetes mellitus rats

By Ohta T.   Furukawa N.   Yonemori F.   Wakitani K.  

European Journal of Pharmacology, Vol. 367, Iss. 1, 1999-02 ,pp. : 91-99

Elsevier

Access to resources Recommend Favorite

Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative

By Shibata T.   Matsui K.   Nagao K.   Shinkai H.   Yonemori F.   Wakitani K.  

European Journal of Pharmacology, Vol. 364, Iss. 2, 1999-01 ,pp. : 211-219

Elsevier

Access to resources Recommend Favorite

Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease?

By Irwin Nigel   Gault Victor   Flatt Peter R  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 9, 2010-09 ,pp. : 1039-1048

Informa Healthcare

Access to resources Recommend Favorite